ClinicalTrials.gg
Active, not recruitingNCT05507749COOL-PERUpdated Aug 20, 2026

Cyroablation for Pulmonary Vein Isolation Alone in Patients With Early Persistent AF Assessed by Continuous Monitoring

An interventional study of cryoballoon ablation and implantable loop recorder insertion in Atrial Fibrillation, Persistent, sponsored by Seoul National University Hospital. Active, not recruiting at 1 site in South Korea. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Seoul National University Hospital · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Nov 2020, registered Aug 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
130
Allocation
Not applicable
Ages
20 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Atrial Fibrillation by Seoul National University Hospital — 6 open to participants now, 7 under way, none of them phase 3. Atrial Fibrillation · Seoul National University Hospital.

Enrollment
7th of 12
130 · median 140
Started
2020
with 1 other
No phase
10 of 18
5 open now
Registered
9th of 18
by date

Among the 18 studies in Atrial Fibrillation by Seoul National University Hospital, this one is the 7th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2020, is one of 10 with no phase, and was the 9th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

6 of the 18 studies in Atrial Fibrillation by Seoul National University Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 20 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Atrial Fibrillation by Seoul National University Hospital, or all of them as a file.
02

Study summary

This study aimed to evaluate the efficacy of Cryoablation in patients with early persistent atrial fibrillation as a first index procedure using continuous cardiac rhythm monitoring.

Read the detailed description

Atrial fibrillation is the most common cardiac arrhythmia. With the population aging, the prevalence of atrial fibrillation is increasing globally. Recently, Cryoablation has been demonstrated non-inferior efficacy and safety compared with catheter ablation in atrial fibrillation patients. Cryoablation with the simplicity of the procedure brought the substantial shortening of the total procedure time compared to catheter ablation with comparable long-term atrial fibrillation free survival and procedure-related adverse events. However, most of the previous studies that reported non-inferior efficacy and safety of Cryoablation versus catheter ablation were only included patients with paroxysmal atrial fibrillation. The long-term efficacy of Cryoablation in patients with persistent atrial fibrillation is controversial.

In patients with persistent atrial fibrillation, pulmonary vein isolation alone showed comparable atrial fibrillation recurrence rate compared to pulmonary vein isolation with additional ablation, including linear ablation or ablation of complex fractionated electrograms.

In a recent study, Cryoablation was safe and had good outcomes in patients with persistent and long-standing persistent atrial fibrillation within relatively short procedure time; atrial fibrillation recurrence rate was 36% in persistent atrial fibrillation and 43% in long-standing persistent atrial fibrillation. Among patients with persistent atrial fibrillation ≤1 year, pulmonary vein isolation using cryoballoon had 39% of any atrial fibrillation/atrial tachycardia recurrence rate during a 1-year follow-up. Pre-predictor such as smaller left atrium size or atrial fibrillation history less than three years was associated with a better outcome of atrial fibrillation cryoablation. Therefore, early ablation of persistent atrial fibrillation using Cryoablation may be related to a good outcome that is nearly comparable to those with paroxysmal atrial fibrillation. Namely, pulmonary vein isolation by Cryoablation could be reasonable as the first procedure in patients with early persistent atrial fibrillation. Based on the results of the STOP Persistent atrial fibrillation trial, the Arctic Front Advance cryoablation system (Medtronic) was granted an expanded indication by the US Food and Drug Administration for the treatment of recurrent, drug-refractory, symptomatic, persistent atrial fibrillation. It is the first ablation catheter in the United States to receive an indication for persistent-as opposed to paroxysmal-atrial fibrillation.

Not only atrial fibrillation recurrence merely defined as any atrial fibrillation episode lasting 30 seconds or more, but the atrial fibrillation burden is also a relevant indicator for evaluation of procedure success. Among patients with paroxysmal atrial fibrillation, a recent prospective study reported that atrial fibrillation burden dramatically decreased after Cryoablation by 99% . There was limited data about the efficacy of Cryoablation in patients with early persistent atrial fibrillation evaluated by actual atrial fibrillation burden using continuous cardiac rhythm monitoring.

03

Conditions studied

  • Atrial Fibrillation, Persistent

Browse trials for

Keywords

  • Cryoablation
04

Who can participate

Ages eligible
20 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Drug symptomatic persistent atrial fibrillation diagnosed within 3 years
  • Either two conditions

    1. atrial fibrillation episode lasting longer than 7 days, but less than 3 years documented by consecutive recordings of 100% atrial fibrillation greater than 7 days apart or
    2. atrial fibrillation episode requiring electrical or pharmacological cardioversion after 24 hours of atrial fibrillation documented by continuous recording
  • Willing to comply with study requirements and give to participate in this clinical study

Exclusion criteria

Exclusion Criteria:

  • Long-standing persistent atrial fibrillation more than 3 years
  • Sinus rhythm at enrollment
  • Recurrent sinus rhythm after electrical cardioversion
  • Severe left ventricular dysfuncion (left ventricle \< 30%)
  • Previous ablation procedure or surgery for atrial fibrillation
  • to chronic anticoagulation therapy or heparin
  • Documented left atrial diameter >50 mm from parasternal long-axis view
  • A percutaneous coronary intervention or myocardial infarction ≤3 months
  • A stroke or ≤6 months
  • Planned cardiovascular intervention
  • Mental or physical inability to participate in the study
  • Participation in another randomized clinical trial
  • Uncontrolled hypertension, untreated hypothyroidism or hyperthyroidism
  • Requirement for dialysis due to terminal renal failure
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
130 participants (actual)

Study arms

  • Experimental
    a group of participants receive implantable loop recorder before cryoballoon ablation

    Following enrollment, an implantable loop recorder is implanted in all participants for the purpose of arrhythmia (any atrial fibrillation or atrial tachycardia) detection (Reveal LINQ, Medtronic, Minneapolis, MN).

    Procedure: cryoballoon ablation · Device: implantable loop recorder insertion

Interventions

  • Procedurecryoballoon ablation

    Cryoballoon ablation for the treatment of atrial fibrillation

  • Deviceimplantable loop recorder insertion

    The device called a implantable loop recorder, is placed just under the skin of one's chest during a minor surgery.

06

What researchers measure

Primary outcomes

  1. Change of implantable cardiac monitor-detected atrial fibrillation/atrial flutter burden.

    The percentage of time spent in atrial fibrillation (hours of atrial fibrillation/hours of monitoring) during the first year after pulmonary vein isolation (excluding a 3-month window) compared to pre-ablation atrial fibrillation/atrial flutter burden.

    Time frame: After cryoablation (between 3-month and 1-year) and pre-ablation

Secondary outcomes

  1. Time to the first recurrence of atrial fibrillation/atrial flutter

    Atrial fibrillation/atrial flutter recurrence, defined as an episode of atrial arrhythmia beyond the first 3 months post-ablation (blanking period), lasting for 30 seconds or more

    Time frame: From 3-month after cryoablation to the removal of the implantable loop recorder, up to 3years.

  2. Recurrence nature of atrial fibrillation

    paroxysmal atrial fibrillation or persistent atrial fibrillation

    Time frame: From 3-month after cryoablation to the removal of the implantable loop recorder, up to 3years.

  3. 36-Item Short Form Health Survey composite scores

    Quality of life assessed with the use of the Medical Outcomes Study 36-Item Short-From Health Survey \[SF-36\]; range 0 to 100, with higher scores indicating better quality of life

    Time frame: Pre-ablation and 1-year after ablation

  4. European Heart Rhythm Association score

    The European Heart Rhythm Association score of atrial fibrillation (or EHRA score) is a classification system for the extent of atrial fibrillation. It places patients in one of four categories based on how much they are limited during physical activity; the limitations/symptoms are in regard to normal breathing and varying degrees in shortness of breath and/or angina. EHRA Class / Symptoms I- No symptoms. II- Mild symptoms; normal daily activity not affected. III- Severe symptoms; normal daily activity affected. IV- Disabling symptoms; normal daily activity discontinued.

    Time frame: Pre-ablation and 1-year after ablation

  5. Atrial fibrillation/atrial flutter recurrence and changes in atrial fibrillation/atrial flutter burden

    Atrial fibrillation/atrial flutter recurrence and changes in AF/AT burden from 3-month after cryoablation to the removal of the implantable loop recorder

    Time frame: From 3-month after cryoablation to the removal of the implantable loop recorder, up to 3years.

07

Study locations

1 site
  • Seoul National university Hostpital
    Seoul, Jongno-gu 03080, South Korea
08

References and documents

Publications

  • Lee SR, Choi EK, Lee KY, Choi J, Ahn HJ, Kwon S, On YK, Lee JH, Cho Y, Oh IY, Lim HE, Cho MS, Nam GB, Lip GYH, Oh S. Reduction of AF Burden After Cryoballoon Ablation in Patients With Early Persistent AF: The COOL-PER Trial. JACC Clin Electrophysiol. 2025 Jun;11(6):1234-1247. doi: 10.1016/j.jacep.2025.02.006. Epub 2025 Mar 26. PubMed 40146092 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Dec 2026, 73 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 73 months is above that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2022
First posted
Aug 19, 2022
StartActual
Nov 27, 2020
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05507749
Responsible party
Eue-Keun Choi (Professor, Seoul National University Hospital) — Principal investigator
First posted
Aug 19, 2022
Start date
Nov 27, 2020
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Aug 20, 2026

Study contacts

Eue-Keun Choi, M.D. Ph.D.
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion